SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018
[X]	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to __________________
For the quarterly period ended September 30, 2018
[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________________ to __________________

Commission File Number: 000-54905

Cantabio Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-54905	99-0373067
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1250 Oakmead Pkwy Sunnyvale, California (Address of principal executive offices)		94085 (Zip Code)
1250 Oakmead Pkwy Sunnyvale, California		94085
(Address of principal executive offices)		(Zip Code)

844-200-2826

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ [X] Yes ☐ [ ] No

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). ☒ [X] Yes ☐ [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐[ ] Accelerated filer ☐[ ] Non-accelerated filer ☐[X] ~~(Do not check if a smaller reporting company)~~ Smaller reporting company ☒[X] Emerging Growth Company ☐[ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ [ ] Yes ☒ [X] No

As of ~~August~~ 17November 9, 2018, there were 5681,~~510~~950,~~521~~977 shares of the issuer’s common stock issued and outstanding.

CANTABIO PHARMACEUTICALS, INC

FORM 10-Q

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Interim Financial Statements (Unaudited)	2	2
	Condensed Consolidated Balance Sheets as of June 30, 2018 and March 31, 2017		2
	Condensed Consolidated Balance Sheets as of September 30, 2018 and March 31, 2017	2
	Condensed Consolidated Statements of Operations for the three months ended June 30, 2018 and 2017		3
	Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2018 and 2017	3
	Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2018 and 2017		4
	Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2018 and 2017	4
	Notes to Condensed Consolidated Financial Statements	5	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12	12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13	13
Item 4.	Controls and Procedures	14	14
PART II – OTHER INFORMATION
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	15	14
Item 1A.	Risk Factors		14
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		14
Item 3.	Defaults Upon Senior Securities	15
Item 3.	Defaults Upon Senior Securities		14
Item 4.	Mine Safety Disclosures	15
Item 4.	Mine Safety Disclosures		14
Item 5.	Other Information	15
Item 5.	Other Information		14
Item 6.	Exhibits	15
Item 6.	Exhibits		15
SIGNATURES		16
SIGNATURES			16

PART I – FINANCIAL INFORMATION

CANTABIO PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	June 30,	March 31,
	2018	2018
ASSETS
Current Assets
Cash	$185,236	$109,426
Prepaid expenses	-	-
Total Current Assets	185,236	109,426
TOTAL ASSETS	$185,236	$109,426
LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued expenses	657,871	606,751
Accrued technology access fee	158,968	171,105
Secured convertible debentures	1,371,126	947,160
Convertible debt related party	300,512	257,614
Total Current Liabilities	2,488,477	1,982,630
TOTAL LIABILITIES	$2,488,477	$1,982,630
Stockholders' Equity (Deficit)
Common stock, $0.001 par value, (250,000,000 shares authorized, 53.9 million and 51.9 million shares issued and outstanding as of June 30, 2018 and March 31, 2018, respectively)	53,864	51,857
Stock subscriptions	1,060,000	1,060,000
Additional paid in capital	1,169,584	1,134,763
Accumulated deficit	(4,586,689)	(4,119,824)
Total Stockholders' Equity (Deficit)	(2,303,241)	(1,873,204)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$185,236	$109,426

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

~~CANTABIO~~PART ~~PHARMACEUTICALS,~~I ~~INC.~~- FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED ~~STATEMENTS~~INTERIM OFFINANCIAL ~~OPERATIONS~~STATEMENTS (UNAUDITED)

~~(Unaudited)~~CANTABIO PHARMACEUTICALS, INC.

	June 30, 2018	June 30,2017
Operating Expenses
Research and development	$111,220	$97,192
General & administrative	124,653	190,733
Total Operating Expenses	235,873	287,925
Loss From Operations	(235,873)	(287,925)
Other Income & (Expenses)
Interest expense	(348,992)	(74,471)
Change in fair value of embedded derivatives, including modification accounting	118,000	10,000
Total Other Income & (Expenses)	(230,992)	(64,471)
Net Loss	$(466,865)	$(352,396)
Basic and Diluted Loss per share	$(0.01)	$(0.01)
Weighted average number of common shares outstanding	53,031,199	27,004,613

CONSOLIDATED BALANCE SHEETS

~~The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.~~(Unaudited)


	September 30, 2018		March 31, 2018

ASSETS
Current Assets
Cash	$	21,527	$	109,426
Total Current Assets		21,527		109,426

TOTAL ASSETS	$	21,527	$	109,426

LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued expenses		641,354		606,751
Accrued technology access fee		162,217		171,105
Secured convertible debentures		1,479,690		947,160
Convertible debt related party		161,148		257,614
Total Current Liabilities		2,444,409		1,982,630

TOTAL LIABILITIES	$	2,444,409	$	1,982,630

Stockholders' Equity (Deficit)
Common stock, $0.001 par value, (250,000,000 shares authorized, 78.5 million and 51.9 million shares issued and outstanding as of September 30, 2018 and March 31, 2018, respectively)		78,537		51,857
Stock subscriptions		1,060,000		1,060,000
Additional paid in capital		1,593,884		1,134,763
Accumulated deficit		(5,155,303)		(4,119,824)
Total Stockholders' Equity (Deficit)		(2,422,882)		(1,873,204)

TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$	21,527	$	109,426

~~CANTABIO~~The ~~PHARMACEUTICALS,~~accompanying ~~INC~~notes are an integral part of these unaudited condensed consolidated financial statements.

~~CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS~~3

~~(Unaudited)~~CANTABIO PHARMACEUTICALS, INC.

	Three Months Ended
	June 30,	June 30,
	2018	2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$(466,865)	$(352,396)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion to notes payable to related party	-	1,266
Amortization of debt discount	328,233	58,130
Change in fair value of embedded derivative	(118,000)	(10,000)
Share based compensation for services	10,000	39,549
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	51,120	87,955
Accrued technology access fee	(12,137)	10,012
Accrued debenture interest	18,459	10,062
Due to officers	-	-
Prepaid Expenses	-	1,248
Net cash used in operating activities	(189,190)	(154,274)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible debt related party, net of issuance cost	265,000	127,000
Proceeds from issuance of convertible debenture, net of issuance cost	-	-
Proceeds from notes payable related party	-	-
Repayment to notes payable related party	-	-
Share subscriptions	-	-
Net cash provided by financing activities	265,000	127,000
Net increase (decrease) in cash	75,810	(27,274)
Cash at beginning of period	109,426	32,275
Cash at end of period	$185,236	$5,001
Schedule of non-cash financing activities
Recognition of beneficial conversion feature associated with convertible debentures	$-	$35,000
Conversion of secured convertible debentures	58,733	-
Share based compensation for services	10,000	39,549

CONSOLIDATED STATEMENTS OF OPERATIONS

~~The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.~~(Unaudited)


	For the three months ended September 30,				For the six months ended September 30,
	2018		2017		2018		2017

Operating expenses:
Research & development	$	79,003	$	98,904	$	190,223	$	196,096
General & administrative		155,128		177,435		279,780		368,169
Total operating expenses		234,131		276,339		470,003		564,265

Loss from operations		(234,131)		(276,339)		(470,003)		(564,265)

Other income (expense):
Interest expense		(288,693)		(112,952)		(637,684)		(187,423)
Change in fair value of embedded derivatives, including modification accounting		2,000		44,000		120,000		54,000
Loss on extinguishment of debt, related party		(91,621)		-		(91,621)		-
Gain on extinguishment of debentures		43,829		-		43,829		-
Total Other Income & (Expenses)		(334,485)		(68,952)		(565,476)		(133,423)

Net loss	$	(568,616)	$	(345,291)	$	(1,035,479)	$	(697,688)

Basic and Diluted Loss per share	$	(0.01)	$	(0.01)	$	(0.02)	$	(0.03)

Weighted average number of common shares outstanding		58,430,000		27,284,000		55,745,000		27,145,000

~~CANTABIO~~The ~~PHARMACEUTICALS,~~accompanying ~~INC~~notes are an integral part of these unaudited condensed consolidated financial statements.

~~Notes to Condensed Consolidated Financial Statements~~4

~~(Unaudited)~~CANTABIO PHARMACEUTICALS, INC.

~~NOTE~~CONDENSED 1CONSOLIDATED –STATEMENTS ~~ORGANIZATION AND DESCRIPTION~~ OF ~~THE BUSINESS~~CASH FLOWS

~~Cantabio Pharmaceuticals Inc.~~ (~~the “Company” or “Cantabio”~~Unaudited) is a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from research and development activities for Parkinson’s disease (PD) and Alzheimer’s disease (AD). The Company’s strategy involves integration of therapeutic focus, the targeting of family biophysics, drug discovery technology and expertise into an innovative drug discovery approach, which synergizes to identify and develop small molecule pharmacological chaperones for clinical trials. In addition, the Company’s research efforts concentrate on the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins with display loss of function during disease conditions.

NOTE 2 – LIQUIDITY AND GOING CONCERN


	Six Months Ended September 30,
	2018		2017

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(1,035,479)	$	(697,688)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on extinguishment of debt related party		91,621		-
Gain on extinguishment of debentures		(43,829)		-
Loss on extinguishment of obligation		17,500		-
Amortization of debt discount		594,621		156,406
Change in fair value of embedded derivative		(120,000)		(54,000)
Share based compensation for services		10,000		39,549
Changes in operating assets and liabilities:
Accounts payable and accrued expenses		104,601		232,564
Accrued technology access fee		(8,888)		17,688
Accrued debenture interest		36,954		21,153
Prepaid Expenses		-		1,248
Net cash used in operating activities		(352,899)		(283,080)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible debt related party, net of issuance cost		265,000		175,000
Proceeds from issuance of convertible debenture, net of issuance cost		-		127,000
Net cash provided by financing activities		265,000		302,000

Net increase (decrease) in cash		(87,899)		18,920

Cash at beginning of period		109,426		32,275
Cash at end of period	$	21,527	$	51,195

Schedule of non-cash financing activities
Recognition of beneficial conversion feature associated with convertible debentures	$	-	$	35,000
Conversion of secured convertible debenture	$	118,785	$	-
Conversion of convertible debt related party	$	269,517	$	-
Issuance of shares for settlement of accounts payable	$	70,000	$	27,178

AsThe ofaccompanying ~~June~~notes ~~30,~~are ~~2018,~~an ~~the~~integral ~~Company~~part ~~had a working capital deficit~~ of ~~approximately~~ ~~$2.3~~these ~~million~~unaudited ~~and~~condensed ~~continues~~consolidated tofinancial ~~have losses from operations due to its research and development activities~~statements.

The Company typically raises capital which it spends on maintaining its research and corporate operations. At this early stage in the life of the Company funding is often short term in nature. While the Company has been proficient in raising funds in the past the short-term nature of these funding cycles raises substantial doubt about the Company's ability to continue as a going concern within one year from the date of this filing.5

~~Management~~CANTABIO ~~is addressing going concern risk by seeking new sources of capital and is continuing initiatives to raise capital through private placements~~PHARMACEUTICALS, ~~related party loans and other institutional sources to meet future working capital requirements~~INC. Furthermore, strategic partnerships, most likely with larger pharmaceutical industry companies, will be needed to continue to fund research and development costs as our projects expand. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company for at least twelve months from issuance of these condensed consolidated financial statements.

~~The~~Notes ~~ability of the Company~~ to ~~continue~~Condensed asConsolidated aFinancial going concern is dependent upon its ability to raise additional capital and achieve profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.Statements

~~NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES~~(Unaudited)

~~Interim~~NOTE ~~Reporting~~1 - ORGANIZATION AND DESCRIPTION OF THE BUSINESS

~~The~~Cantabio ~~accompanying~~Pharmaceuticals ~~unaudited~~Inc. ~~condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in~~ (the ~~United~~“Company” ~~States~~or (“~~U.S. GAAP~~Cantabio”) ~~for~~is ~~interim~~a ~~financial~~preclinical ~~information~~stage ~~and~~biotechnology ~~with~~company ~~the instructions~~focusing toon ~~Form~~commercializing ~~10-Q~~novel therapies and ~~Article~~the 10intellectual ofproperty ~~Regulation~~generated ~~S-X. Accordingly,~~from ~~certain~~research ~~information~~ and ~~footnote~~development ~~disclosures~~activities ~~normally included~~for inParkinson’s ~~annual~~disease ~~financial~~(PD) ~~statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities~~ and ~~Exchange~~Alzheimer’s ~~Commission~~disease (~~“SEC”~~AD). ~~rules~~The ~~and regulations~~Company’s ~~and~~strategy ~~accounting~~involves ~~principles~~integration ~~applicable~~of ~~for~~therapeutic ~~interim periods.~~focus, In the ~~opinion~~targeting of ~~management~~family biophysics, ~~all~~drug ~~adjustments~~discovery ~~(consisting of~~technology ~~normal~~and ~~recurring~~expertise ~~accruals)~~into ~~considered~~an ~~necessary~~innovative ~~for~~drug adiscovery ~~fair presentation~~approach, ~~have~~which ~~been~~synergizes ~~included. Events subsequent~~ to ~~the~~identify ~~balance sheet~~and ~~date~~develop ~~have~~small ~~been~~molecule ~~evaluated~~pharmacological chaperones for ~~inclusion~~clinical intrials. ~~the~~In ~~accompanying condensed~~addition, ~~consolidated financial statements through~~ the ~~date~~Company’s ~~of issuance.~~research ~~Operating~~efforts ~~results~~concentrate ~~for~~on the ~~three~~development ~~months ended June 30, 2018 are not necessarily indicative~~ of ~~the~~therapeutic ~~results~~proteins that ~~may~~can ~~be expected~~pass ~~for~~through the ~~year~~blood-brain ~~ending~~barrier ~~March 31, 2019. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements~~ and ~~the notes~~supplement ~~thereto included~~ in ~~the~~vivo ~~Annual~~levels ~~Report~~of onproteins ~~Form~~with ~~10-K~~display ~~for~~loss ~~the fiscal~~of ~~year~~function ~~ended~~during ~~March~~disease ~~31, 2018~~conditions.

~~Use~~NOTE of2 ~~Estimates~~- GOING CONCERN

~~The~~As ~~preparation~~ of ~~financial~~September ~~statements~~30, in2018, ~~conformity with GAAP requires management to make estimates and assumptions that affect~~ the ~~reported~~Company ~~amounts~~had ofa ~~assets~~working ~~and~~capital ~~liabilities~~deficit and ~~disclosure~~continues ~~of contingent~~to ~~assets~~have ~~and~~losses ~~liabilities~~from atoperations ~~the~~due ~~date~~to ~~of the financial statements and the reported amounts of expenses during the year. Management bases~~ its ~~estimates~~research ~~on historical experience~~ and ~~on other~~development ~~assumptions considered to be reasonable under the circumstances~~activities. ~~However, actual results may differ from the estimates.~~

~~Earnings~~The ~~(Loss)~~Company ~~per~~typically ~~Share~~raises capital which it spends on maintaining its research and corporate operations. At this early stage in the life of the Company funding is often short term in nature. While the Company has been proficient in raising funds in the past the short-term nature of these funding cycles raises substantial doubt about the Company's ability to continue as a going concern within one year from the date of this filing.

~~The~~Management ~~Company~~is ~~calculates~~addressing ~~earnings~~going ~~per~~concern ~~share~~risk ~~using~~by ~~basic~~seeking ~~net~~new ~~income (loss)~~sources ~~per~~of ~~common~~capital ~~share~~and is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet future working capital requirements. Furthermore, strategic partnerships, most likely with larger pharmaceutical industry companies, will be ~~computed~~needed byto ~~dividing~~continue ~~net~~to ~~income~~fund ~~(loss) for~~research ~~the~~and ~~period~~development bycosts ~~the~~as ~~weighted~~our ~~average~~projects ~~number~~expand. ofThese ~~common~~measures, ~~shares outstanding~~if ~~during~~successful, may contribute to reduce the ~~period.~~risk ~~The~~of going concern uncertainties for the Company ~~does~~for ~~not~~at ~~compute~~least ~~diluted earnings~~twelve ~~per~~months ~~share~~from ~~because~~issuance toof dothese socondensed ~~would~~consolidated ~~be anti-dilutive~~financial statements.

5The ability of the Company to continue as a going concern is dependent upon its ability to raise additional capital and achieve profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

~~CANTABIO~~NOTE ~~PHARMACEUTICALS,~~3 ~~INC.~~- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

~~Notes~~Interim ~~to Condensed Consolidated Financial Statements~~Reporting

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (~~Unaudited~~“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (“SEC”) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the three months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending March 31, 2019. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended March 31, 2018.

~~Potentially dilutive securities~~6

	June 30,	June 30,
	2018	2017
Convertible debentures (Note 6)	25,007,000	5,865,000
Convertible debt related party (Note 7)	5,908,000	-
Stock subscriptions	530,000	530,000

Use of Estimates

~~Recent~~The ~~Accounting~~preparation ~~Standards~~of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.

~~Fiscal~~Earnings ~~2019~~(Loss) ~~Accounting~~per ~~Pronouncement Adoptions~~Share

InThe ~~August~~Company ~~2016,~~calculates ~~the~~earnings ~~FASB~~per ~~issued~~share ~~ASU~~using ~~No.~~basic ~~2016-15,~~net ~~Statement~~income ~~of Cash Flows~~ (~~Topic 230~~loss): ~~Classification~~per ofcommon ~~Certain~~share ~~Cash~~be ~~Receipts~~computed ~~and~~by ~~Cash Payments.~~dividing ~~This~~net ~~new~~income ~~standard~~(loss) ~~clarifies~~for ~~certain aspects of~~ the ~~statement~~ ofperiod ~~cash~~by ~~flows, including~~ the ~~classification~~weighted ofaverage ~~debt prepayment~~number ~~or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate~~ of ~~the~~common ~~borrowing,~~shares ~~contingent consideration~~outstanding ~~payments~~during ~~made after a business combination, proceeds from~~ the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactionsperiod. ~~This~~The ~~new~~Company ~~standard~~does ~~also clarifies~~not ~~that~~compute andiluted ~~entity~~earnings ~~should~~per ~~determine~~share ~~each~~because ~~separately identifiable~~to ~~source~~do ofso ~~use~~would within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be ~~separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item~~anti-dilutive. ~~This new standard became effective the Company for us on April 1, 2018. The new standard does not have a material impact on our financial statements.~~

~~Recently~~Potentially ~~Issued~~dilutive ~~Accounting Pronouncements~~securities

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Certain qualitative and quantitative disclosures are required, as well as a retrospective recognition and measurement of impacted leases. The new ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements.


	September 30,	September 30,
	2018	2017
Convertible debentures (Note 6)	59,045,000	11,331,000
Convertible debt related party (Note 7)	7,843,000	5,450,000
Stock subscriptions	530,000	530,000

InRecent ~~June 2018, the FASB issued~~ Accounting Standards Update (ASU) 2018-07 intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. This ASU expands the scope of Topic 718, Compensation-Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity-Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other companies, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company's adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements.

6Fiscal 2019 Accounting Standards Adoptions

~~CANTABIO~~In ~~PHARMACEUTICALS~~August 2016, ~~INC~~the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. This new standard became effective for the Company on April 1, 2018. The new standard does not have a material impact on our financial statements.

~~Notes~~Recently toIssued ~~Condensed~~Accounting ~~Consolidated Financial Statements~~Standards

In February 2016, the FASB issued ASU 2016-02, Leases (~~Unaudited~~Topic 842). ASU 2016-02 increases the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Certain qualitative and quantitative disclosures are required, as well as a retrospective recognition and measurement of impacted leases. The new ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements.

~~NOTE~~In 4June –2018, ~~RELATED~~the ~~PARTY~~FASB ~~TRANSACTIONS~~issued Accounting Standards Update (ASU) 2018-07 intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. This ASU expands the scope of Topic 718, Compensation-Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity-Equity-Based Payments to Nonemployees.

~~There have been no changes to the Company’s related party consulting arrangements as they have been disclosed in our most recently filed form 10K.~~7

7The amendments in this ASU are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other companies, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company's adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements.

~~CANTABIO~~SEC ~~PHARMACEUTICALS,~~Disclosure ~~INC.~~Update and Simplification

~~Notes~~In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to ~~Condensed~~the ~~Consolidated~~ending ~~Financial~~balance ~~Statements~~of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements.

~~(Unaudited)~~NOTE 4 - RELATED PARTY TRANSACTIONS

~~Costs~~There ~~incurred~~have ~~associated~~been ~~with~~no changes to the Company’s related party ~~transactions~~consulting ~~noted above~~arrangements ~~included~~as inthey ~~general~~have ~~and~~been ~~administrative~~disclosed in ~~the~~our ~~statement~~most ~~of operations~~recently ~~are~~filed asform ~~follows:~~10K.

	For the three months ended June 30,
	2018	2017
Operating expenses:
Toth and Associates LTD	$44,000	$40,000
Capro LTD	24,000	33,000
Eden Professional LTD	23,000	21,000
Max Zhu Consulting (1)	3,000	6,000
Total related party transactions	$94,000	$100,000

Costs incurred associated with related party transactions included in general and administrative in the statement of operations are as follows:

(1)


	For the six months ended September 30,
	2018		2017

Operating expenses:
Toth and Associates LTD	$	87,000	$	80,000
Capro LTD		48,000		66,000
Eden Professional LTD		45,000		42,000
Max Zhu Consulting		6,000		12,000

Total related party transactions	$	186,000	$	200,000

~~Max Zhu,~~Accounts anpayable ~~investor in~~ and ~~lender~~accrued toexpenses ~~the~~includes ~~Company,~~amounts ~~also~~payable ~~works~~to asrelated ~~Head~~ parties of ~~Computer~~$0.3 ~~Aided~~and ~~Drug~~$0.6 ~~Design~~million for the ~~Company~~period ~~under~~ended aSeptember ~~consultancy contract~~30, 2018 and March 31, 2018, respectively.

~~Accounts~~NOTE ~~payable~~5 ~~and~~- ~~accrued~~CONVERTIBLE ~~expenses~~DEBENTURES ~~includes~~AS ~~amounts payable to related parties of $0.7 and $0.6 million for the period ended June 30, 2018 and March 31, 2018, respectively.~~AMENDED

~~NOTE~~New ~~5 – CONVERTIBLE DEBENTURES AS AMENDED~~issuance

~~New~~On June 5, 2018 the Company entered into a new securities purchase agreement with an accredited investor to place Convertible Debentures (as amended the “Debentures”) in the aggregate principal amount of up to $300,000 net of issuance costs of $35,000 (the “Transaction”). The Debentures bear interest at the rate of 5% per annum with a maturity date of June 5, 2019, as may be extended at the option of the note holder. In addition, the Company must pay to the holder an annual fee equal to 7% of the amount of the Debentures to assist in their monitoring costs for the Debentures. The net proceeds of the financing were used for general corporate matters and for other expenses. The Debentures may be converted at any time on or prior to maturity at the lower of $0.05 or 93% of the average of the three lowest daily volume weighted average price (“VWAP”) during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the Debenture and the conversion price is never lower than a stated floor price.

On June 5, 2018 the Company entered into a new securities purchase agreement with an accredited investor to place Convertible Debentures (as amended the “Debentures”) in the aggregate principal amount of up to $300,000 net of issuance costs of $35,000 (the “Transaction”). The Debentures bear interest at the rate of 5% per annum with a maturity date of June 5, 2019, as may be extended at the option of the note holder. In addition, the Company must pay to the holder an annual fee equal to 7% of the amount of the Debentures to assist in their monitoring costs for the Debentures. The net proceeds of the financing were used for general corporate matters and for other expenses. The Debentures may be converted at any time on or prior to maturity at the lower of $0.05 or 93% of the average of the three lowest daily volume weighted average price (“VWAP”) during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the Debenture and the conversion price is never lower than a stated floor price.8

At the same time all previous debentures were amended to align them with the new agreement. All the Debentures may be converted at any time on or prior to maturity at the lower of $0.05 or (rather than $0.10 as previously) or 93% of the average of the three lowest daily volume weighted average price (“VWAP”) during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the Debenture and the conversion price is never lower than a stated floor price. The Company accounted for the amendment as a debt modification which resulted in $76,000 impact that was recorded in the change in fair value of embedded derivatives in the Company’s statements of operations.Amendment

8At the same time all previous debentures were amended to align them with the new agreement. All the Debentures may be converted at any time on or prior to maturity at the lower of $0.05 (rather than $0.10 as previously) or 93% of the average of the three lowest daily volume weighted average price (“VWAP”) during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the Debenture and the conversion price is never lower than a stated floor price. The Company accounted for the amendment as a debt modification which resulted in $76,000 impact that was recorded in the change in fair value of embedded derivatives in the Company’s statements of operations.

~~CANTABIO~~Embedded ~~PHARMACEUTICALS, INC.~~Derivative

~~Notes~~Embedded toDerivatives ~~Condensed~~- ~~Consolidated~~Monthly ~~Financial~~Payment ~~Statements~~Provision

~~(Unaudited)~~The monthly payment provision within the Debentures is a contingent put option that is required to be separately measured at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statements of Operations. The Company estimated the fair value of the monthly payment provision, as of the issuance date and September 30, 2018 using probability analysis of the occurrence of a Triggering Date applied to the discounted maximum redemption premium for any given payment.

~~Embedded~~The ~~Derivatives~~probability analysis utilized in calculating the embedded derivative at September 30, 2018 and March 31, 2018 was calculated using the following key inputs:

~~The monthly~~Monthly ~~payment~~Payment provision within the Debentures is a contingent put option that is required to be separately measured at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statements of Operations. The Company estimated the fair value of the monthly payment provision, as of the issuance date and June 30, 2018 using probability analysis of the occurrence of a Triggering Date applied to the discounted maximum redemption premium for any given payment. The probability analysis utilized in calculating the embedded derivative upon issuance and at June 30, 2018 was calculated using the following key inputs:Provision

	June 30, 2018	March 31, 2018
	September 30, 2018		March 31, 2018
Stock price	$0.04017	~~$0.06~~	$0.06
Probability of Triggering Date	100%	~~100%~~	100%
Volatility	300%	~~300%~~	300%
Risk-free rate	1%	1%	1%
Discount rate	0%	0%	0%

Due to the ~~extinguishment of the notes and the~~ Company’s sequencing policy the ~~amended notes the~~ Company recorded an embedded derivative associated with the conversion feature. The following are the inputs associated with the conversion feature.

	June 30, 2018	March 31, 2018
Stock price	$0.04 - $0.06	$0.06
Exercise price	$0.04 - $0.06	$0.06
Volatility	300%	300%
Contractual term	0.42 - 1 year	1 year
Risk-free rate	1%	1%
Discount rate	0%	0%

Conversion Feature

The fair value estimate of the embedded derivatives is a Level 3 measurement. The roll-forward of the Level 3 fair value measurement, for the three months ended June 30, 2018, is as follows:


	September 30, 2018	March 31, 2018
Stock price	$0.017	$0.06
Exercise price	$0.016	$0.06
Volatility	400%	300%
Contractual term	0.14 - 0.68 year	1 year
Risk-free rate	1%	1%
Discount rate	0%	0%

Balance at March 31, 2018	Issuance of new debentures	Change due to modification	Net unrealized (gain)/loss	Balance at June 30, 2018
736,000	$281,000	$76,000	$(195,000)	$898,000

The fair value estimate of the embedded derivatives is a Level 3 measurement. The roll-forward of the Level 3 fair value measurement, for the six months ended September 30, 2018, is as follows:

The approximate carrying value of the Debentures, as of June 30, 2018 and March 31, 2018 is comprised of the following:

Balance at

March 31, 2018

Issuance of

new debentures

Change due to

modification

Net realized

(gain)/loss

Conversion

Balance at

September 30, 2018

$ 736,000

$ 281,000

$ 76,000

$ (200,000)

$ (65,000)

$ 828,000

	June 30, 2018	March 31, 2018
Principal value of 5%, convertible, net of conversion	$1,000,000	$750,000
Fair value of embedded derivative	898,000	736,000
Accrued interest	23,000	22,264
Debt discount	(550,000)	(561,104)
Carrying value of Secured Convertible Debenture Note	$1,371,000	$947,160

AsThe ofapproximate ~~June~~carrying ~~30,~~value ~~2018,~~of the ~~estimated~~Debentures, ~~aggregate~~as ~~fair value~~ of ~~outstanding~~ ~~convertible~~September ~~notes~~30, ~~payable~~2018 isand ~~approximately~~March ~~$1.4 million.~~31, ~~The~~2018 ~~fair value estimate~~ is ~~based~~comprised ~~on the estimated option value~~ of the ~~conversion terms. The estimated fair value represents a Level 3 measurement.~~following:

Convertible debenture


	September 30, 2018		March 31, 2018
Principal value of 5%, convertible, net of conversion	$	916,000	$	750,000
Fair value of embedded derivatives		828,000		736,000
Accrued interest		34,000		22,264
Debt discount		(298,000)		(561,104)
Carrying value of Secured Convertible Debenture Note	$	1,480,000	$	947,160

~~During~~As ~~the~~of ~~three~~September ~~months ended June~~ 30, 2018, ~~holders~~the estimated aggregate fair value of outstanding convertible notes payable is approximately $0.1.5 million. inThe ~~principal~~fair ~~amount~~value ~~and~~estimate ~~accrued~~is ~~interest with~~based ~~respect~~on tothe ~~Secured~~estimated ~~Convertible~~option ~~Debentures~~value ~~exercised~~of the conversion ~~option~~terms. ~~and~~The ~~converted~~estimated ~~into~~fair ~~1.6~~value ~~million~~represents ~~shares~~a ofLevel ~~common stock~~3 measurement.

~~Events~~Secured ofConvertible ~~Default~~Debenture ~~or Financial covenants~~Conversions

~~The~~During ~~Company~~the issix months ended September 30, 2018, holders of approximately $0.16 million in ~~compliance~~principal ~~with~~amount ~~all~~and ~~terms~~accrued ~~associated~~interest with respect to Secured Convertible Debentures exercised the conversion option and converted into 7.1 million shares of common stock. The fair market value of the shares issued of $0.12 million was less than the net carrying value of the convertible ~~note~~notes by $0.04 million and a gain on extinguishment was recorded.

9Events of Default or Financial covenants

~~CANTABIO~~The ~~PHARMACEUTICALS,~~Company ~~INC~~is in compliance with all terms associated with the convertible note.

~~Notes~~NOTE to6 ~~Condensed~~- ~~Consolidated~~CONVERTIBLE ~~Financial~~DEBT ~~Statements~~RELATED PARTY

~~(Unaudited)~~Overview

~~NOTE~~The 6carrying –value ~~CONVERTIBLE~~of ~~DEBT~~the ~~RELATED~~Notes, ~~PARTY~~as of September 30, 2018 and March 31, 2018 is comprised of the following:

The analysis utilized in calculating the embedded derivative at June 30, 2018 and March 31, 2018 was calculated using the following key inputs:


	September 30, 2018		March 31, 2018
Principal value of 5%, convertible, net of conversion	$	120,000	$	220,000
Fair value of embedded derivatives		95,000		156,000
Accrued interest		4,800		15,204
Debt discount		(58,000)		(133,590)
Carrying value of Secured Convertible Debenture Note	$	161,000	$	257,614

	June 30, 2018	March 31, 2018
Stock price	$0.04	$0.02- $0.07
Contractual term	0.1 - 0.5 years	0.1 - 1.0 years
Volatility	300%	275% - 300%
Risk-free rate	1%	1%

As of September 30, 2018, the estimated aggregate fair value of outstanding convertible notes payable is approximately $0.2 million. The fair value estimate is based on the estimated option value of the conversion terms. The estimated fair value represents a Level 3 measurement.

~~The fair value estimate of the embedded derivative is a Level 3 measurement. The roll-forward of the Level 3 fair value measurement, for the three months ended June 30, 2018, is as follows:~~Conversions

Balance at March 31, 2018	Net unrealized (gain)/loss	Balance at June 30, 2018
$156,000	$(1,000)	$157,000

In September 2018 the holder converted $100,000 of principal and $25,789 of interest into approximately 10.7 million shares of common stock. The fair market value of the shares issued of $0.3 million exceeded the net carrying value of the convertible notes by $0.1 million and a loss on extinguishment was recorded.

~~The~~Embedded ~~carrying value of the Notes, as of June 30, 2018 and March 31, 2018 is comprised of the following:~~features

	June 30, 2018	March 31, 2018
Principal value of 5%, convertible	$220,000	$220,000
Fair value of embedded conversion option	157,000	156,000
Accrued Interest	23,704	15,204
Debt discount	(100,192)	(133,590)
Carrying value of Secured Convertible Debenture Note	$300,512	$257,614

The analysis utilized in calculating the embedded derivative at September 30, 2018 and March 31, 2018 was calculated using the following key inputs:

As of June 30, 2018, the estimated aggregate fair value of outstanding convertible notes payable is approximately $0.2 million. The fair value estimate is based on the estimated option value of the conversion terms. The estimated fair value represents a Level 3 measurement.


	September 30, 2018	March 31, 2018
Stock price	$0.017	$0.06
Contractual term	0.27 years	0.1 - 1.0 years
Volatility	400%	300%
Risk-free rate	1%	1%

~~Technical default~~10

The ~~notes~~fair ~~which~~value ~~are~~estimate ~~due~~of ~~in January 2018 are in technical default, although~~ the ~~obligation~~embedded ~~has~~derivative ~~not~~is ~~been~~a ~~called~~Level by3 ~~the lender~~measurement. The ~~note agreement~~roll-forward ~~provided~~of ~~for~~the ~~such~~Level ~~circumstances~~3 ~~with~~fair ~~the~~value ~~effect~~measurement, ~~that~~for the ~~Company~~ issix ~~currently~~months ~~accruing~~ended ~~the~~September ~~interest~~30, at2018, ~~the~~is ~~default~~as ~~interest rate of 28%.~~follows:

Balance at

March 31, 2018

Conversion

Net unrealized

(gain)/loss

Balance at

September 30, 2018

$ 156,000

$ (65,000)

$ 4,000

$ 95,000

~~CANTABIO~~Technical ~~PHARMACEUTICALS, INC.~~default

~~Notes~~The toremaining ~~Condensed~~note ~~Consolidated~~which ~~Financial~~was ~~Statements~~due in July 2018 is in technical default, although the obligation has not been called by the lender.

~~(Unaudited)~~NOTE 7 - CAPITAL STOCK

~~NOTE~~Issuance 7of –shares ~~CAPITAL~~for ~~STOCK~~consulting services.

~~Issuance~~During ofthe six months ended September 30, 2018 the Company issued approximately 0.4 million shares ~~for~~with ~~consulting~~a fair value of approximately $10,000 as compensation for services performed, and issued approximately 8.6 million shares to Directors of the company in lieu of $70,000 of unpaid fees.

~~During~~NOTE ~~the~~8 ~~three~~- ~~months~~SUBSEQUENT ~~ended June 30, 2018 the Company issued approximately 0.4 million shares with a fair value of approximately $10,000 as compensation for services performed.~~EVENTS

~~NOTE~~The 8Company –issued ~~SUBSEQUENT~~a ~~EVENTS~~convertible loan note to a related party for $115,000. The loan matures in 6 months, and earns interest at 24% before maturity and 29% thereafter, with conversion terms substantially similar to those already existing

OnA ~~July 26, 2018 a~~ holder of convertible debentures converted approximately $0.14 million of principal and interest into approximately 23.64 million shares of common stock.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this report.

This Quarterly Report contains forward-looking statements about our business, financial condition and prospects that reflect management’s assumptions and beliefs based on information currently available. The expectations indicated by such forward-looking statements might not be realized. If any of our management’s assumptions should prove incorrect, or if any of the risks and uncertainties underlying such expectations should materialize, our actual results may differ materially from those indicated by the forward-looking statements.

The key factors that are not within our control and that may have a direct bearing on operating results include, but are not limited to, managements’ ability to raise capital in the future, the retention of key employees and changes in the regulation of our industry. There may be other risks and circumstances that management may be unable to predict.

When used in this Quarterly Report, words such as, "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions.

As of ~~June~~September 30, 2018, we had approximately $~~185~~22,000 cash in the bank. This amount will not satisfy our cash requirements for the next twelve months. We plan to satisfy our future cash requirements by additional equity financing. This will likely be in the form of private placements of common stock. Additional equity financing may not be available to us on acceptable terms or at all, and thus we could fail to satisfy our future cash requirements.

If we are unsuccessful in raising the additional proceeds through a private placement offering, we will then have to seek capital from other sources such as debt financing, which may not be available to us. However, if such financing were available, we would likely have to pay additional costs associated with high risk loans and be subject to an above market interest rate. At such time these funds are required, management would evaluate the terms of such debt financing and determine whether the business could manage the debt load. If we cannot raise additional proceeds via a private placement of our common stock or secure debt financing we would be required to cease as a business. As a result, investors in our common stock would lose all of their investment.

Results of Operations for the three months ended ~~June~~September 30, 2018, as compared to the three months ended ~~June~~September 30, 2017.

Our operating expenses decreased to $~~235~~234,~~873~~131 for the three months ended ~~June~~September 30, 2018 from $~~287~~276,~~925~~339 in the three months ended ~~June~~ September 30, 2017. The R&D spend of $~~111~~79,~~220~~003 in the three months to ~~June~~ September 30, 2018 compares with $9798,~~192~~904 on R&D in the same period in 2017, ~~the increase being~~ due ~~additional~~to ~~spend~~headcount onhaving ~~third~~reduced ~~party contract~~between ~~research~~the ~~organisations~~two periods. There was a decrease ~~of approximately $66,000~~ in General and Administrative expenses to $~~124~~155,~~653~~128 in the three months to ~~June~~September 30, 2018 from $~~190~~177,~~733~~435 in the three months to ~~June~~September 30, 2017. The decrease was largely driven by decreased legal and professional fees related to fundraising activities ~~and decreased investor relations spend~~.

We generated Other Expense in the three months ended ~~June~~September 30, 2018 of $~~230~~334,~~992~~485 made up of $~~348~~288,~~992~~693 of interest expense, the overwhelming majority of which relates to amortization of debt discount connected with convertible instruments, ~~and~~ a $~~118~~2,000 gain in fair value of an embedded derivative, and a net $47,792 loss on extinguishment of debt and debentures. Other Expense for the same period of 2017 was $6468,~~471~~952, made up of ~~was~~ $74112,~~471~~952 of interest expense, partially offset by a $1044,000 gain in fair value of an embedded derivative.

~~Liquidity~~Results ~~and~~of ~~Capital~~Operations ~~Resources~~for the six months ended September 30, 2018, as compared to the six months ended September 30, 2017.

OnOur ~~June~~operating ~~30,~~expenses ~~2018~~decreased to $470,003 wefor ~~had~~the ~~approximately~~six months ended September 30, 2018 from $~~185~~564,~~000~~265 in ~~current~~the ~~assets~~six months ended September 30, ~~consisting~~ ~~entirely~~2017. R&D spend of ~~cash.~~$190,223 ~~Our~~in ~~total~~the ~~current~~six ~~liabilities~~months asto ~~of June~~September 30, 2018, ~~were~~compared ~~approximately~~to $2196,~~488,000~~096 in the same period in 2017 driven by lower staff costs in 2017 partially offset by higher third-party R&D costs. ~~Thus,~~There wewas ~~had~~a ~~negative working~~decrease ~~capital~~in ofGeneral ~~approximately~~and Administrative expenses to $2279,~~303,000~~780 asin ofthe ~~June~~six months to September 30, 2018 from $368,169 in the same period in 2017 largely driven by reduction in legal and professional fees which were high in 2017 due to fundraising activities.

~~Cash~~Other ~~Flows~~Expense ~~from~~in ~~Financing Activities. During~~ the ~~three~~six months ended ~~June~~September 30, 2018 was $565, ~~financing~~476 ~~activities~~made ~~provided~~up of $~~265~~637,~~000~~684 ~~from~~of ainterest expense, the majority of which relates to amortization of debt discount connected with convertible ~~debenture facility~~instruments, and $47,792 net loss on extinguishment of debt and debentures, offset by a gain in the value of embedded derivatives of $120,000. ~~This~~In ~~compares~~the six months to ~~approximately~~September 30, 2017 Other Expense was $~~127~~133,~~000~~423 ~~from~~made ~~a convertible~~up ~~debenture~~of ~~facility~~$187,423 of interest expense, offset by a gain in the ~~same~~value ~~period~~of ~~in 2017~~embedded derivatives of $54,000.

~~The~~Liquidity ~~Company typically raises capital which it spends on maintaining its research~~ and ~~corporate~~Capital operations. At this early stage in the life of the Company funding is often short term in nature. While the Company has been proficient in raising funds in the past, the short-term nature of these funding cycles raises substantial risk around the Company's ability to continue as a going concern.Resources

~~Management~~On isSeptember ~~addressing~~30, ~~going~~2018, ~~concern~~we ~~risk~~had byapproximately ~~seeking~~$22,000 ~~new~~in ~~sources of~~current ~~capital and is continuing initiatives to raise capital through private placements~~assets, ~~related~~consisting ~~party~~entirely ~~loans~~of ~~and~~cash. ~~other~~Our ~~institutional sources~~total tocurrent ~~meet~~liabilities ~~future~~as ~~working~~of ~~capital~~September ~~requirements. Furthermore~~30, ~~strategic~~ ~~partnerships~~2018, ~~most~~were ~~likely~~approximately ~~with~~$2,444,000. ~~larger pharmaceutical industry companies~~Thus, ~~will~~we behad ~~needed~~negative toworking ~~continue~~capital toof ~~fund~~approximately ~~research and development costs as our projects expand. These measures~~$2, ~~if successful~~422,000 ~~may~~as ~~contribute to reduce the risk~~ of ~~going~~September ~~concern uncertainties~~30, ~~for the Company beyond the next twelve months~~2018.

~~Our~~Cash ~~financial~~Flows ~~statements~~from ~~indicate~~Financing ~~there~~Activities. isDuring ~~substantial~~the ~~doubt~~six ~~about our~~months ~~ability~~ended toSeptember ~~continue~~30, as2018, afinancing ~~going~~activities ~~concern~~provided as$265,000 ~~this~~from ~~would~~a ~~depend upon~~convertible ~~our~~debenture ~~ability~~facility. toThis ~~obtain~~compares ~~ongoing financing and ultimately~~ to ~~generate~~ ~~sufficient~~approximately ~~cash~~$127,000 ~~flow~~from ~~to meet our obligations on~~ a ~~timely basis.~~convertible ~~Our~~debenture ~~plans~~facility and ~~efforts~~approximately ~~to achieve the above steps might not be successful~~$175,000 ~~which~~from ~~raises~~related ~~substantial~~party ~~doubt~~convertible ~~about~~notes ~~the~~in ~~Company's ability to continue as a going concern within one year from~~ the ~~date~~ ofsame ~~this~~period ~~filing~~in 2017.

~~OFF~~The ~~BALANCE~~Company ~~SHEET~~typically ~~ARRANGEMENTS~~raises capital which it spends on maintaining its research and corporate operations. At this early stage in the life of the Company, funding is often short term in nature. While the Company has been proficient in raising funds in the past, the short-term nature of these funding cycles raises substantial risk around the Company's ability to continue as a going concern.

~~The~~Management ~~Company~~is ~~does~~addressing ~~not~~going ~~have~~concern ~~any~~risk ~~off-balance~~by ~~sheet~~seeking ~~arrangements~~new ~~that have~~sources orof ~~are~~capital ~~reasonably~~and ~~likely~~is continuing initiatives to ~~have~~raise acapital ~~current~~through orprivate placements, related party loans and other institutional sources to meet future ~~effect~~working ~~on the~~capital ~~Company's~~requirements. Furthermore, ~~financial~~strategic ~~condition~~partnerships, ~~changes~~most inlikely ~~financial~~with ~~condition, revenues~~larger orpharmaceutical ~~expenses~~industry companies, ~~results~~will ofbe ~~operations~~needed to continue to fund research and development costs as our projects expand. These measures, ~~liquidity~~if successful, ~~capital expenditures~~may orcontribute ~~capital~~to ~~resources~~reduce ~~that~~the ~~are~~risk ~~material~~of ~~to investors~~going concern uncertainties for the Company beyond the next twelve months.

~~Item~~Our 3financial statements indicate there is substantial doubt about our ability to continue as a going concern as this would depend upon our ability to obtain ongoing financing and ultimately to generate sufficient cash flow to meet our obligations on a timely basis. ~~Quantitative~~Our plans and ~~Qualitative~~efforts ~~Disclosures~~to achieve the above steps might not be successful, which raises substantial doubt about ~~Market Risk~~the Company's ability to continue as a going concern within one year from the date of this filing.

~~Not~~OFF ~~applicable.~~BALANCE SHEET ARRANGEMENTS

13The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

~~Item~~ITEM 43. ~~Controls~~QUANTITATIVE ~~and~~AND ~~Procedures~~QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ANot set of disclosure controls and procedures designed to ensure that information required to be disclosed by us in the reports filed under the Securities Exchange Act, is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms is required to be maintained by managementapplicable. Disclosure controls should be designed with the objective of ensuring that this information is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. Management has not designed and currently does not maintain a designed set of disclosure controls and procedures.

We have not evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. As a result, management has concluded that our disclosure controls and procedures were not effective for the year ended June 30, 2018, due to the following:13

1ITEM 4. CONTROLS AND PROCEDURES

~~Failure~~ A set of disclosure controls and procedures designed to ~~design~~ensure that information required to be disclosed by us in the reports filed under the Securities Exchange Act, is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms is required to be maintained by management. Disclosure controls should be designed with the objective of ensuring that this information is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. Management has not designed and currently does not maintain a designed set of disclosure controls and ~~control~~ procedures.

2We have not evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. As a result, management has concluded that our disclosure controls and procedures were not effective for the quarter ended September 30, 2018, due to the following:

~~Lack of segregation of duties as a result of limited personnel~~1.

3.Failure to design and maintain a set of disclosure and control procedures

~~Lack of Functioning Audit Committee - We do not have an Audit Committee, our board of directors currently acts as our Audit Committee~~2. ~~We do not have an independent director.~~

~~PART~~Lack ~~II: OTHER~~of ~~INFORMATION~~segregation of duties as a result of limited personnel.

~~Item 1~~3. ~~Legal Proceedings.~~

~~None~~Lack of Functioning Audit Committee - We do not have an Audit Committee, our board of directors currently acts as our Audit Committee. We do not have an independent director.

~~Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.~~14

OnPART ~~April~~II ~~30,~~- ~~2018,~~OTHER a holder of a convertible debenture converted $58,733 of interest and principal on such debenture into 1,636,013 shares of our common stock at $0.0359 per share pursuant to the terms of such debenture.INFORMATION

OnITEM ~~May~~1. ~~12,~~LEGAL ~~2018, we issued 370,370 shares of our common stock to a supplier in satisfaction of invoices worth $10,000~~PROCEEDINGS.

~~On July 26, 2018, a holder of a convertible debenture converted $51,192 of interest and principal on such debenture into 2,646,937 shares of our common stock at $0~~None.~~01934 per share pursuant to the terms of such debenture.~~

~~Item~~ITEM 32. ~~Defaults~~UNREGISTERED ~~Upon~~SALES ~~Senior~~OF ~~Securities~~EQUITY SECURITIES AND USE OF PROCEEDS.

~~None~~On September 11, 2018, a holder of a convertible debenture converted $34,329 of principal and interest on such debenture into 2,795,502 shares of our common stock at $0.01228 per share pursuant to the terms of such debenture.

~~Item~~On 4September 20, 2018, a holder of a convertible note converted $125,789 of principal and interest on such loan into 10,652,853 shares of our common stock at $0.011808 ~~Mine~~per ~~Safety~~share ~~Disclosures~~pursuant to the terms of such loan.

~~None~~On September 20, 2018, we issued 8,578,431 shares of our common stock to our Directors in lieu of unpaid fees totalling $70,000 at a price of $0.00816.

~~Item~~On 5October 17, 2018, a holder of a convertible debenture converted $40,008 of principal and interest on such debenture into 3,413,670 shares of our common stock at $0.01172 ~~Other~~per ~~Information~~share pursuant to the terms of such debenture.

~~None~~ITEM 3. DEFAULTS UPON SENIOR SECURITIES

14None.

~~Item~~ITEM 64. ~~Exhibits~~ MINE SAFETY DISCLOSURES

31.1	Certification of Principal Executive Officer and Acting Principal Accounting Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
32.1	Certification of the Principal Executive Officer and Acting Principal Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

None

~~Exhibit~~ITEM ~~101~~5. OTHER INFORMATION

~~101~~None.~~INS - XBRL Instance Document~~

~~101~~ITEM 6.~~SCH~~ ~~- XBRL Taxonomy Extension Schema Document~~EXHIBITS

101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document


Exhibit No.	Description
31.1	Certification of Principal Executive Officer and Acting Principal Accounting Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
32.1	Certification of the Principal Executive Officer and Acting Principal Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

~~101.DEF - XBRL Taxonomy Extension Definition Linkbase Document~~15

~~101.LAB - XBRL Taxonomy Extension Label Linkbase Document~~SIGNATURES

~~101.PRE~~In -accordance ~~XBRL~~with ~~Taxonomy~~the ~~Extension~~requirements ~~Presentation~~of ~~Linkbase Document~~the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

15Cantabio Pharmaceuticals Inc.

~~SIGNATURES~~By: /s/ Gergely Toth

InGergely ~~accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~Toth

~~Cantabio~~Its: ~~Pharmaceuticals~~President, ~~Inc~~Chief Executive Officer, Director (Principal Executive Officer).

~~By:~~November ~~/s/~~13, ~~Gergely Toth~~2018

~~Gergely~~By: ~~Toth~~/s/ Simon Peace

~~Its:~~Simon ~~President, Chief Executive Officer, Director (Principal Executive Officer).~~Peace

~~August~~Its: 20Chief Financial Officer, ~~2018~~Director (Principal Accounting Officer)

~~By:~~November ~~/s/~~13, ~~Simon Peace~~2018

~~Simon Peace~~16

Its: Chief Financial Officer, Director (Principal Accounting Officer)

August 20, 2018

Filing Compare · Cantabio Pharmaceuticals Inc.